Last updated on November 2018

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Brief description of study

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Clinical Study Identifier: NCT03052608

Contact Investigators or Research Sites near you

Start Over

Pfizer Call Center

Florida Cancer Specialists
New Port Richey, FL United States
  Connect »